Tianeptinaline
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Tianeptinaline is a histone deacetylase (HDAC) inhibitor which was derived via structural modification of the tricyclic antidepressant (TCA) tianeptine.
Tianeptinaline is a histone deacetylase (HDAC) inhibitor which was derived via structural modification of the tricyclic antidepressant (TCA) tianeptine.
Pharmacology
Tianeptinaline potently inhibits the class I HDAC1, HDAC2, and HDAC3 with values of 240 nM, 120 nM, and 155 nM, whereas it did not inhibit the class II HDAC5 or HDAC6 ( = >80,000 nM). Potential actions against other HDACs, such as HDAC4, HDAC7, HDAC8, and HDAC9, were not described.
The drug has been found to enhance CREB-mediated transcription, penetrate into the brain, and enhance contextual fear conditioning, a behavioral measure of hippocampus-dependent memory, in rodents.
Chemistry
The chemical synthesis of tianeptinaline has been described. Another analogue of tianeptinaline, known as tianeptinostat, is also a potent HDAC inhibitor. However, whereas tianeptinaline did not inhibit HDAC6, tianeptinostat was a highly potent inhibitor of HDAC6 in addition to the class I HDACs.
History
Tianeptinaline and tianeptinostat were first described in the scientific literature by 2018. They were derived from tianeptine after it was noted that tianeptine has a similar chemical structure to that of the potent clinically used HDAC inhibitor vorinostat (SAHA) and that tianeptine itself is a weak HDAC inhibitor ( = 25,000 nM, 82,000 nM, and >2 mM at HDAC1, HDAC2, and HDAC3, respectively).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368087378 under CC BY-SA 4.0; modifications have been made.